Preliminary results from a FIH, open-label phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab

被引：0
|
作者：
Perets, Ruth
Meshner, Shiri
Tirosh, Osnat
Eshar, Shiri
Metz-Breiner, Alona
Ben-Shabat, Sheerli Kruger
Ben-Yehuda, Hila
Haber, Elran
Cohen-Asis, Meital
Maurice-Dror, Corinne
Ringel, Yehuda
Holland, Roy
Shirman, Yelena
Kutiel, Talia Shentzer
机构：
[1] Technion Israel Inst Technol, Rambam Hlth Care Campus, Haifa, Israel
[2] Biomica, Rehovot, Israel
[3] BC Canc Agcy, Vancouver, BC, Canada
[4] Rambam Med Ctr, Haifa, Israel
[5] Rambam Hlth Care Campus, Div Oncol, Haifa, Israel
[6] Rambam Med Ctr, Haifa, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8631
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study
    Ravit Geva
    Juanita Lopez
    Sarah Danson
    Heikki Joensuu
    Avivit Peer
    Samuel J. Harris
    Fabricio Souza
    Kaline M. C. Pereira
    Ruth Perets
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1092 - 1101
  • [22] Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
    Laetsch, Theodore W.
    DuBois, Steven G.
    Mascarenhas, Leo
    Turpin, Brian
    Federman, Noah
    Albert, Catherine M.
    Nagasubramanian, Ramamoorthy
    Davis, Jessica L.
    Rudzinski, Erin
    Feraco, Angela M.
    Tuch, Brian B.
    Ebata, Kevin T.
    Reynolds, Mark
    Smith, Steven
    Cruickshank, Scott
    Cox, Michael C.
    Pappo, Alberto S.
    Hawkins, Douglas S.
    LANCET ONCOLOGY, 2018, 19 (05): : 705 - 714
  • [23] Interferon beta-1a and atorvastatin combination therapy: 12-month results from an open-label, randomized, clinical study
    Orefice, Giuseppe
    Quarantelli, Mario
    Salvatore, Petronilla
    Brunetti, Arturo
    Lanzillo, Roberta
    Prinster, Anna
    Vacca, Giovanni
    Mollica, Carmine
    Bonauita, Vincenzo
    Morra, Vincenzo Brescia
    NEUROLOGY, 2008, 70 (11) : A85 - A85
  • [24] N-Acetylmannosamine (ManNAc) for the Treatment of GNE Myopathy: 18-Month Preliminary Results from a Phase 2 Open-Label Study
    Huizing, Marjan
    Class, Bradley
    Quintana, Melanie
    Slota, Christina
    Leoyklang, Petcharat
    Glowacki, Ashleigh
    Bradley, Kennan
    Ciccone, Carla
    Malicdan, May Christine V.
    Berry, Scott M.
    Gahl, William A.
    Carrillo, Nuria
    GLYCOBIOLOGY, 2017, 27 (12) : 1219 - 1219
  • [25] Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction study
    Dow, James
    Currie, Alexander
    He, Ling
    Zaidi, Faisal
    Zahir, Hamim
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (10) : 451 - 458
  • [26] OLANZAPINE AND SAMIDORPHAN IN PEDIATRIC PATIENTS WITH BIPOLAR I DISORDER: PHARMACOKINETIC RESULTS FROM A PHASE 1, MULTIDOSE, OPEN-LABEL STUDY
    DelBello, Melissa P.
    Zhang, Liming
    Landry, Ishani
    McDonnell, David
    Finlayson, Lara
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2024, 63 (10): : S209 - S209
  • [27] Radium-223 in Combination with Paclitaxel in Cancer Patients wiith Bone Metastases: Safety Results from an Open-Label, Multicenter Phase 1b Study
    Lopez, J. S.
    Perets, R.
    Danson, S.
    Joensuu, H.
    Peer, A.
    Harris, S. J.
    Souza, F.
    Ploeger, B.
    Pereira, K. M. C.
    Geva, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S132 - S133
  • [28] ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study
    Naoe, Tomoki
    Sakura, Toru
    Kobayashi, Yukio
    Usuki, Kensuke
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Morita, Satoshi
    Bahceci, Erkut
    Kaneko, Masahito
    Yamada, Shunsuke
    Takeshita, Shigeru
    Miyawaki, Shuichi
    BLOOD, 2015, 126 (23)
  • [29] Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer
    Goldman, Jonathan W.
    Waterhouse, David M.
    George, Ben
    O'Dwyer, Peter J.
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal U.
    Ong, Teng Jin
    Kelly, Karen
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [30] ARIES: A PHASE 2, OPEN-LABEL STUDY TO EVALUATE RUCAPARIB (PARP INHIBITOR) IN COMBINATION WITH NIVOLUMAB (ANTI-PD-1 ANTIBODY) IN PATIENTS WITH OVARIAN OR UROTHELIAL CANCER (UC)
    Moore, K.
    Redhead, K.
    Goble, S.
    Bowles, O.
    Lin, K. K.
    Tripathi, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A130 - A130
12345